Stock News

As Sensata Technologies (ST) Market Valuation Declined, Holder Night Owl Capital Management Trimmed Its Position; Aquinox Pharmaceuticals (AQXP) Holding Maintained by University Of Notre Dame Du Lac

Sensata Technologies Holding PLC (NYSE:ST) Logo

University Of Notre Dame Du Lac increased its stake in Aquinox Pharmaceuticals Inc (AQXP) by 31.96% based on its latest 2017Q4 regulatory filing with the SEC. University Of Notre Dame Du Lac bought 60,808 shares as the company’s stock rose 24.91% while stock markets declined. The institutional investor held 251,091 shares of the health care company at the end of 2017Q4, valued at $2.95M, up from 190,283 at the end of the previous reported quarter. University Of Notre Dame Du Lac who had been investing in Aquinox Pharmaceuticals Inc for a number of months, seems to be bullish on the $301.41M market cap company. The stock decreased 3.46% or $0.46 during the last trading session, reaching $12.83. About 29,033 shares traded. Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) has declined 8.81% since April 19, 2017 and is downtrending. It has underperformed by 20.36% the S&P500.

John Kim decreased its stake in Sensata Technologies (ST) by 42% based on its latest 2017Q4 regulatory filing with the SEC. Night Owl Capital Management Llc sold 35,765 shares as the company’s stock declined 1.54% with the market. The hedge fund run by John Kim held 49,399 shares of the industrial machinery and components company at the end of 2017Q4, valued at $2.53M, down from 85,164 at the end of the previous reported quarter. Night Owl Capital Management Llc who had been investing in Sensata Technologies for a number of months, seems to be less bullish one the $9.32B market cap company. The stock decreased 1.05% or $0.57 during the last trading session, reaching $53.85. About 296,360 shares traded. Sensata Technologies Holding PLC (NYSE:ST) has risen 18.02% since April 19, 2017 and is uptrending. It has outperformed by 6.47% the S&P500.

Among 6 analysts covering Aquinox Pharma (NASDAQ:AQXP), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Aquinox Pharma had 18 analyst reports since September 11, 2015 according to SRatingsIntel. Canaccord Genuity maintained it with “Buy” rating and $22.0 target in Monday, November 20 report. The company was maintained on Thursday, November 9 by Cantor Fitzgerald. The stock of Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) earned “Hold” rating by Jefferies on Friday, August 5. On Friday, October 23 the stock rating was initiated by Needham with “Buy”. Canaccord Genuity maintained Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) rating on Monday, December 11. Canaccord Genuity has “Buy” rating and $22.0 target. The stock has “Hold” rating by Jefferies on Tuesday, March 15. Cantor Fitzgerald maintained Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) on Monday, March 12 with “Buy” rating. Guggenheim initiated it with “Buy” rating and $22 target in Tuesday, October 6 report. Needham maintained the shares of AQXP in report on Tuesday, August 8 with “Buy” rating. Cantor Fitzgerald maintained Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) rating on Sunday, February 11. Cantor Fitzgerald has “Buy” rating and $28.0 target.

University Of Notre Dame Du Lac, which manages about $481.90 million US Long portfolio, decreased its stake in Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) by 11,802 shares to 20,095 shares, valued at $2.55M in 2017Q4, according to the filing. It also reduced its holding in Insmed Inc (NASDAQ:INSM) by 115,292 shares in the quarter, leaving it with 87,121 shares, and cut its stake in Ally Finl Inc (NYSE:ALLY).

Analysts await Sensata Technologies Holding PLC (NYSE:ST) to report earnings on April, 24 before the open. They expect $0.84 earnings per share, up 18.31% or $0.13 from last year’s $0.71 per share. ST’s profit will be $145.32M for 16.03 P/E if the $0.84 EPS becomes a reality. After $0.87 actual earnings per share reported by Sensata Technologies Holding PLC for the previous quarter, Wall Street now forecasts -3.45% negative EPS growth.

Night Owl Capital Management Llc, which manages about $517.84M and $214.64 million US Long portfolio, upped its stake in Shopify by 13,460 shares to 77,420 shares, valued at $7.82M in 2017Q4, according to the filing.

Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) Ratings Chart

Leave a Reply

Your email address will not be published. Required fields are marked *